What is the role of advanced lipoprotein analysis in practice?

Journal of the American College of Cardiology

Volumn 60, Issue 25, 2012, Pages 2607-2615

  Robinson, Jennifer G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

analysis; apolipoprotein B; clinical; lipoprotein

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; FENOFIBRATE; FISH OIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GLYCEMIC CONTROL; GOUT; HEART ATRIUM FIBRILLATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MUSCLE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SKIN DISEASE; STOMACH ULCER;

EID: 84871258228     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.04.067     Document Type: Review

References (59)

1. National Cholesterol Education Panel Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
2. S.M. Grundy, J.I. Cleeman, C.N.B. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
3. P.M. Ridker, E. Danielson, F.A.H. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
4. H.R. Superko Advanced lipoprotein testing and subfractionation are clinically useful Circulation 119 2009 2183 2195
5. A. Sniderman, C. Furberg, A. Keech Apoliproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 2003 777 780 (Pubitemid 36293636)
6. J.D. Brunzell, M. Davidson, C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 2008 1512 1524 (Pubitemid 351470037)
7. J. Genest, R.F.J. McPherson, T. Anderson Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
8. Ž. Reiner, A.L. Catapano, G. De Backer ESC/EAS guidelines for the management of dyslipidaemias Eur Heart J 32 2011 1769 1818
9. P. Greenland, J.S. Alpert, G.A. Beller 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance J Am Coll Cardiol 56 2010 e50 e103
10. D. Steinberg Thematic review series: the pathogenesis of atherosclerosis An interpretive history of the cholesterol controversy: part I J Lipid Res 45 2004 1583 1593
11. J.G. Robinson, A.C. Goldberg Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on familial hypercholesterolemia J Clin Lipidol 5 Suppl 1 2011 S18 S29
12. S. Mora Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use Circulation 119 2009 2396 2404
13. M.J. McQueen, S. Hawken, X. Wang Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study Lancet 372 2008 224 233 (Pubitemid 351978112)
14. M. Chung, A.H. Lichtenstein, S. Ip, J. Lau, E.M. Balk Comparability of methods for LDL subfraction determination: a systematic review Atherosclerosis 205 2009 342 348
15. H. Superko, R. Gadesam Is it LDL particle size or number that correlates with risk for cardiovascular disease? Curr Atheroscler Rep 10 2008 377 385
16. J. Albers, S. Marcovina, H. Kennedy International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B II. Evaluation and selection of candidate reference materials Clin Chem 38 1992 658-2
17. A.D. Sniderman, A.C. St-Pierre, B. Cantin, G.R. Dagenais, J.-P. Despres, B. Lamarche Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk Am J Cardiol 91 2003 1173 1177 (Pubitemid 36561379)
18. S.M. Grundy, G.L. Vega, J.E. Tomassini, A.M. Tershakovec Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial) Am J Cardiol 108 2011 40 46
19. B.G. Nordestgaard, M.J. Chapman, K. Ray Lipoprotein(a) as a cardiovascular risk factor: current status Eur Heart J 31 2010 2844 2853
20. National Cholesterol Education Program Recommendation on lipoprotein measurement from the Working Group on Lipoprotein Measurement NIH Publication No. 3044 1995 National Institutes of Health, National Heart Lung and Blood Institute Bethesda, MD
21. P. Tung, S.D. Wiviott, C.P. Cannon, S.A. Murphy, C.H. McCabe, C.M. Gibson Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of pravastatin (40 mg) or atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study) Am J Cardiol 103 2009 1056 1060
22. P.P. Glasziou, L. Irwig, S. Heritier, R.J. Simes, A. Tonkin, Lipid Study Investigators for the Monitoring cholesterol levels: measurement error or true change? Ann Intern Med 148 2008 656 661 (Pubitemid 351669110)
23. J.D. Otvos, S. Mora, I. Shalaurova, P. Greenland, R.H. Mackey, D.C. Goff Jr Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
24. P. Manickam, A. Rathod, S. Panaich Comparative prognostic utility of conventional and novel lipid parameters for cardiovascular disease risk prediction: do novel lipid parameters offer an advantage? J Clin Lipidol 5 2011 82 90
25. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
26. A.D. Sniderman, K. Williams, J.H. Contois A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk Circulation: Cardiovasc Qual Outcomes 4 2011 337 345
27. M.A. Hlatky, P. Greenland, D.K. Arnett Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416
28. W.A. van der Steeg, S.M. Boekholdt, E.A. Stein Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk asessment: a case-control analysis in EPIC-Norfolk Ann Intern Med 146 2007 640 648 (Pubitemid 351650519)
29. E. Ingelsson, E.J. Schaefer, J.H. Contois Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 2007 776 785 (Pubitemid 47263160)
30. S. Mora, J.D. Otvos, N. Rifai, R.S. Rosenson, J.E. Buring, P.M. Ridker Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women Circulation 119 2009 931 939
31. P.M. Ridker, N. Rifai, N.R. Cook, G. Bradwin, J.E. Buring Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333 (Pubitemid 41043776)
32. Cholesterol Treatment Trialists Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
33. J.J.P. Kastelein, W. van der Stieg, I. Holme Lipids, apoliproteins, and their ratios in relation to cardiovascular events with statin treatment Circulation 117 2008 3002 3009
34. K.K. Ray, C.P. Cannon, R. Cairns, D.A. Morrow, P.M. Ridker, E. Braunwald Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
35. A.M. Gotto Jr., E. Whitney, E.A. Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484 (Pubitemid 30080860)
36. P.M. Ridker, E. Danielson, F.A.H. Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
37. S. Boekholdt, B. Arsenault, S. Mora Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins JAMA 307 2012 1302 1309
38. B.V. Howard, M.J. Roman, R.B. Devereux Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS Randomized Trial JAMA 299 2008 1678 1689 (Pubitemid 351519865)
39. W. Howard, M. Russell, J. Fleg Prevention of atherosclerosis with low-density lipoprotein cholesterol lowering, lipoprotein changes and interactions: the SANDS study J Clin Lipidol 3 2009 322 331
40. D.C. Goff Jr, H.C. Gerstein, H.N. Ginsberg Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Am J Cardiol 99 Suppl 1 2007 S4 S20
41. The ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
42. J.B. Muhlestein, H.T. May, J.R. Jensen The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) Study J Am Coll Cardiol 48 2006 396 401
43. H.T. May, J.L. Anderson, R.R. Pearson Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen Study) Am J Cardiol 101 2008 486 489 (Pubitemid 351199437)
44. H.E. Bays, S. Conrad, L.A. Leiter Are post-treatment low density lipoprotein subclass analyses potentially misleading? Lipids Health Dis 9 2010 136
45. O. Faergeman, I. Holme, R. Fayyad Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease Am J Cardiol 104 2009 459 463
46. J.C. LaRosa, S.M. Grundy, D.D. Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435 (Pubitemid 40471450)
47. C.P. Cannon, E. Braunwald, C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504 (Pubitemid 38477774)
48. T.R. Pedersen, O. Faergeman, J.J.P. Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL Study: a randomized controlled trial JAMA 294 2005 2437 2445 (Pubitemid 41627921)
49. A.C. Keech, P. Mitchell, P.A. Summanen Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial Lancet 9600 2007 1687 1697 (Pubitemid 350100775)
50. The AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
51. J.R. Guyton, H.E. Bays Safety considerations with niacin therapy Am J Cardiol 99 6 Suppl 1 2007 S22 S31
52. Coronary Drug Project Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 380
53. D. Gordon, J. Probstfield, R. Garrison High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies Circulation 79 1989 8 15 (Pubitemid 19043669)
54. T.J. Smilde, S. van Wissen, H. Wollersheim, M.D. Trip, J.J.P. Kastelein, A.F.H. Stalenhoef Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581 (Pubitemid 32179609)
55. C. Wilson, C.-C. Huang, N. Shara Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) J Clin Lipidol 4 2010 165 172
56. C.L. Gillies, K.R. Abrams, P.C. Lambert Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis BMJ 334 2007 299 308
57. V. Ramjee, L.S. Sperling, T.A. Jacobson Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math J Am Coll Cardiol 58 2011 457 463
58. D. Preiss, S.R.K. Seshasai, P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy JAMA 305 2011 56 64
59. M.H. Davidson, C.M. Ballantyne, T.A. Jacobson Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists J Clin Lipidol 5 2011 338 367